Form of Award NoticeAmgen Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
This notice of Award (the “Award Notice”) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan. The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made of part of the Agreement. Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement.
AMENDMENT NUMBER 1 TO EXPANSION AGREEMENTExpansion Agreement • November 8th, 2010 • Amgen Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT NUMBER 1 to the Expansion Agreement (the “Amendment”) is made and entered into as of the 10th day of September, 2010, by and between Glaxo Group Limited, registered in England as company number 305979, having its principal office at Glaxo Wellcome House, Berkley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”), and Amgen Inc., a Delaware corporation with a place of business at 1 Amgen Center Drive, Thousand Oaks, CA 91320 (“Amgen”).
Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. AMENDMENT NO. 6 TO THE MASTER SERVICES AGREEMENT BY AND...Master Services Agreement • November 8th, 2010 • Amgen Inc • Biological products, (no disgnostic substances)
This Amendment Number 6 (“Amendment”) is entered into effective as of September 23, 2010 (the “Amendment Effective Date”) by and between Amgen Inc. (“Company”) and International Business Machines Corporation (“Supplier”).
